← board
ARMP
distress 7/10 · high distress / dilution risk$5.37+2%today-64% from 52w high
Lead: Staphylococcus aureus bacteremia
Revenue
pre-revenue
Liquidity
$5M
Runway
0.2 yrs
Shares 1y
+1%
Price & events
-13.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
+2.5%
1D
+42.8%
1W
-23.4%
1M
-60.3%
3M
-10.5%
6M
+123.7%
1Y
+79.0%
2Y
+34.2%
5Y
+77.8%
All
Overview
- Market Cap
- $197.13K
- Volume
- 7.79K
- 52 Week Range
- $2.22 – $14.80
- Total Shares
- 36.71K
- Float Shares
- 11.43M
- Short %
- 4.09%
- % Held by Insiders
- 68.55%
- % Held by Institutions
- 10.46%
- RVOL
- 0.04x
- Beta
- 1.27
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 9
- second half of 2026Guided 55%trial initiationsecondaryPhase 3AP-SA02 · initiate Phase 3 superiority studySEC 8-K
- 2026-08-11Estimated 45%earningsEarningsEarnings releaseyahoo
- second half of 2026trial initiationsecondaryPhase 3AP-SA02 · Phase 3 trial to assess superiority over standard of care.SEC 8-K
- 2026-06-23partnershipAP-SA02 · Received $2.5M additional non-dilutive DoD funding, bringing total program funding to $28.7M.SEC 8-K
- 2026-01-13fda agreementAP-SA02 · FDA End-of-Phase 2 written response confirmed safety and efficacy data support advancement to Phase 3 and provided guidance on study design.SEC 8-K
- Q2 2025readoutPhase 1/2AP-SA02 · Topline data from Phase 1b/2a diSArm trialSEC 8-K
- first quarter of 2025readoutPhase 1/2AP-SA02 · Topline data from diSArm studySEC 8-K
- 2025-03-12partnershipsecured $10M credit agreement with InnovivaSEC 8-K
- November 12, 2024enrollment completesecondaryPhase 1/2AP-SA02 · Full enrollment (n=50) achieved in Phase 1b/2a diSArm studySEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $18 (+226% upside) · 2 analysts
- 2026-02-23HC Wainwright & Co.Buy
- 2026-01-05Jones TradingBuy
- 2025-05-19HC Wainwright & Co.Buy
- 2024-12-19HC Wainwright & Co.Buy
- 2024-11-14HC Wainwright & Co.Buy
- 2024-11-12HC Wainwright & Co.Buy
Competitors — Staphylococcus aureus bacteremia
- none identified
Recent news
- 2026-07-21Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar? - Yahoo! Finance Canada
- 2026-07-21Armata Pharmaceuticals (ARMP) Advances Towards Phase 3 Study for AP-SA02 - GuruFocus
- 2026-07-21Armata Pharmaceuticals (ARMP) Advances Superbug Therapy, Stock R - GuruFocus
- 2026-07-21Armata (ARMP) Names David House as New CFO to Lead Financial Str - GuruFocus
- 2026-07-20Why Is Armata Pharma Stock Gaining Monday? - Benzinga
- 2026-07-20Armata Pharmaceuticals (ARMP) Advances Superbug Therapy, Stock R - GuruFocus
- 2026-07-20Armata Pharmaceuticals (ARMP) Advances Superbug Therapy, Stock R - GuruFocus
- 2026-07-20Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02 - Morningstar
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.